ARHGEF25

Across TCGA pan-cancer cohorts, ARHGEF25 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ARHGEF25 data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher ARHGEF25 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARHGEF25 expression acts as an unfavorable survival marker.

BLCA, UCS, and UCEC are the cancer types where ARHGEF25 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.186	0.632	<.001	32	view →
UCS	DFS	Median	II,III,IV	0.090	0.457	.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUSC	DFS	Median	III,IV	0.165	0.623	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ARHGEF25–BLCA (DFS)

Open the BLCA breakdown →